KM Research Hub
← 返回论文库
无 KM 图 入排:排除 图源:开放图源暂不可得 入排置信度 0.98

POYANG: A phase III randomized clinical trial of faricimab for choroidal neovascularization secondary to pathologic myopia: study design and rationale.

Timothy Y Y Lai, Luis Arias, Chui Ming Gemmy Cheung, Aude Couturier, Wenxin Liu, Olivia E O'Leary, Neala Rafijah, Neil Shah, Young Hee Yoon, Shriji Patel, POYANG Study investigators

Graefes Arch Clin Exp Ophthalmol 264(1) 141-148

PMID41152620
PMCID-
DOI10.1007/s00417-025-07000-7
发表日期2025-10-29
入排依据:未发现恶性肿瘤人群证据。
PubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。
摘要

摘要

PURPOSE: To describe the study design of the POYANG study, an international, randomized, double-masked, multicenter, active comparator-controlled Phase 3 trial assessing the efficacy and safety of faricimab, a dual inhibitor of angiopoietin-2 (Ang-2) and vascular endothelial growth factor A (VEGF-A), in patients with choroidal neovascularization secondary to pathologic myopia (mCNV). METHODS: Adult patients with treatment-naïve mCNV will be randomized 1:1 to receive either faricimab 6.0 mg or ranibizumab 0.5 mg. After an initial active intravitreal treatment administration at randomization (Day 1), subsequent treatment will be administered using a pro-re-nata (PRN) dosing regimen. Patients will be seen monthly over a 48-week study period and active study drug will be administered when protocol-defined retreatment criteria are met. Criteria are based on changes in best-corrected visual acuity (BCVA), central subfield thickness (CST) or examination findings consistent with mCNV activity. A sham procedure will be administered to patients at study visits when there is no active mCNV disease activity, in order to maintain masking. RESULTS: This study aims to recruit approximately 280 patients with mCNV from 11 countries in the Asia-Pacific and European regions. The primary endpoint is non-inferiority of faricimab versus ranibizumab in change from baseline in BCVA averaged over Weeks 4, 8 and 12. Secondary endpoints include change in CST over time and number of treatments required. Incidence and severity of ocular and non-ocular adverse events will be assessed. CONCLUSIONS: POYANG is a Phase 3 registrational trial investigating the efficacy and safety of faricimab in patients with choroidal neovascularization secondary to pathologic myopia.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。